| Literature DB >> 25459665 |
Annette Tognela1, Kevin J Spring2, Therese Becker2, Nicole J Caixeiro3, Victoria J Bray4, Po Yee Yip5, Wei Chua6, Stephanie H Lim7, Paul de Souza8.
Abstract
There is increasing evidence for the use of circulating tumor cells (CTCs) as a "liquid biopsy" for early detection of lung cancer recurrence, prognosticating disease and monitoring treatment response. Further, CTC molecular analysis and interrogation of single cells hold significant potential in providing insights into tumor biology and the metastatic process. Ongoing research will likely see the translation of CTCs as a prognostic and predictive biomarker in both small cell, and non-small cell, lung cancer to routine clinical practice. CrownEntities:
Keywords: Biomarkers; Circulating tumor cells; Lung cancer; Non-small cell; Small cell
Mesh:
Substances:
Year: 2014 PMID: 25459665 DOI: 10.1016/j.critrevonc.2014.10.001
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312